Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Multi-Center, Safety and Efficacy Study Evaluating Intravenously Administered 131I-TM601 in Patients With Progressive and/or Recurrent Malignant Melanoma

NCT00733798 is registered in ClinicalTrials.gov with TransMolecular as lead sponsor.

NCT NCT00733798
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00733798 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Multi-Center, Safety and Efficacy Study Evaluating Intravenously Administered 131I-TM601 in Patients With Progressive and/or Recurrent Malignant Melanoma
Lead sponsor
TransMolecular
Phase
Phase 1/2
Overall status
Terminated
Start date
Not reported
Completion date
Not reported
Enrollment
58 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

malignant melanoma, melanoma, metastatic melanoma